President Trump has nominated Dr. Erica Schwartz to lead the Centers for Disease Control and Prevention, adding experienced medical and military leadership as the agency emerges from a chaotic stretch marked by leadership turnover, policy fights over vaccines, and sharp political scrutiny.
Trump named Dr. Erica Schwartz, a Brown University–trained physician, military veteran, and former deputy surgeon general, to take the CDC helm after a year of upheaval. The nomination installs a credentialed public health official at an agency that has seen mass firings, budget cuts, and a shooting at its Atlanta headquarters. The timing makes the pick as much political as professional, coming ahead of November midterms.
The White House move reflects a strategic reset on vaccines and public health messaging tied to polling and the broader Make America Healthy Again agenda. A memo from a Trump pollster warned that “skepticism toward vaccine requirements is politically risky,” and the administration appears to be steering toward less confrontational ground. Schwartz does not carry a prominent anti-vaccine record, which makes her a politically safer choice.
If confirmed by the Senate, Schwartz would be the fourth person to lead the CDC in under a year, a turnover that underscores the agency’s instability. That rapid change at the top has left career staff and outside observers wondering about continuity and institutional memory. A steady, qualified director could help calm internal turbulence if given room to operate.
Schwartz’s résumé combines clinical, public health, and military experience. She served as chief medical officer for the U.S. Coast Guard, held the rank of Rear Admiral in the U.S. Public Health Service, and led disease surveillance programs while writing policies on pandemic influenza, Ebola, and other outbreaks. Trump wrote that Schwartz “graduated from Brown University for College and Medical School, and served a distinguished career as a Doctor of Medicine in the United States Military, the Greatest and Most Powerful Force in the World, and then served as my Deputy Surgeon General during my First Term.” He added simply: “She is a STAR!”
“A battle-tested leader with decades of distinguished public service, including as a Rear Admiral in the U.S. Public Health Service and Coast Guard, she has the expertise, credibility, and integrity to lead the CDC effectively.”
“If allowed to follow the science without political interference, she’ll excel.”
Trump also announced several senior health appointments to build a broader leadership team around Schwartz. Sean Slovenski, a former leader in private-sector health care, will serve as CDC Deputy Director and Chief Operating Officer. Jennifer Shuford, who led a large state public health agency, was tapped as CDC Deputy Director and Chief Medical Officer, and Sara Brenner moves into a senior counseling role at HHS.
The president presented the slate as a restoration of scientific excellence and operational competence. On social platforms he framed the hires as a return to rigorous standards, writing that “These Highly Respected Doctors of Medicine have the knowledge, experience, and TOP degrees to restore the GOLD STANDARD OF SCIENCE at the CDC.” Supporters argue the team blends public health chops with management experience.
“She’s a good executive leader that will be able to right the ship and stabilize a CDC that frankly, has been on its haunches since the COVID response.”
Critics point to the events that precipitated the shake-up: a Senate-confirmed director removed amid vaccine policy clashes, a reconstituted advisory panel bypassed during a childhood vaccine schedule overhaul, and a federal judge blocking parts of that effort. The administration’s push to alter guidance, including changes to an autism-related vaccine page, and real-world consequences such as a child’s death from measles, have intensified scrutiny.
The agency also faced internal crises beyond policy fights: shootings at the Atlanta campus, rounds of firings, and deep budget cuts left morale battered. Career staff say the institution looked like it was in free fall at times, with leadership flux making coordinated public health responses harder. Restoring confidence will require both competent leadership and calmer policy signals.
“This new team is really going to be able to revolutionize CDC and get it back on track and get it doing the job that it does better than any other health agency in the world.”
Health Secretary Kennedy has softened his public tone on vaccines, saying they work “for most people” and noting the new team had “gotten applause from both Republicans and Democrats.” Those comments suggest an awareness of political risk as midterms approach, and a desire to limit the opposition’s leverage. Whether that translates into less disruptive policy choices remains an open question.
“As long as the secretary is in place, it’s unclear to me what will change. They aren’t really systematically changing what they are doing. They’re just publicly messaging differently.”
Skepticism about meaningful change persists, voiced by former agency officials who worry that personnel swaps won’t alter the people and processes above the director’s office. Those concerns focus on whether embedded allies across HHS will still shape outcomes regardless of who occupies the CDC director role. The test is whether Schwartz can translate her military and public health credentials into real institutional authority.
The administration’s calculus is plainly political: polling flagged vaccine messaging as a liability even as other MAHA elements poll well, and the White House wants credible faces leading federal health work. Schwartz’s multiple degrees and flag-officer rank make her hard to dismiss on qualifications alone, but authority and latitude matter as much as credentials. The nomination is a clear attempt to steady a swaying agency while navigating the politics that created the instability.
